Real-World Treatment Patterns of Disease Modifying Therapy (DMT) for Patients with Relapse-Remitting Multiple Sclerosis and Patient Satisfaction with Therapy: Results of the Non-Interventional SKARLET Study in Slovakia

References

• Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol. 2018;25:215–237. doi:10.1111/ene.13536
   PubMed Web of Science ®Google Scholar
• Mendel R, Traul-Mattausch E, Frey D, et al. Do physicians’ recommendations pull patients away from their preferred treatment options? Health Expect. 2012;15(1):23–31. doi:10.1111/j.1369-7625.2010.00658.x
   PubMed Web of Science ®Google Scholar
• Albrecht G, Hoogstraten J. Satisfaction as a determinant of compliance. Community Dent Oral Epidemiol. 1998;26:139–146. doi:10.1111/j.1600-0528.1998.tb01940.x
   PubMed Web of Science ®Google Scholar
• Hirji I, Gupta S, Goren A, et al. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient’s perspective. Health Qual Life Outcomes. 2013;11:167. doi:10.1186/1477-7525-11-167
   PubMed Web of Science ®Google Scholar
• Turk-Adawi K, Oldridge N, Tarima S, Stason W, Shepard D. Cardiac rehabilitation patient and organizational factors: what keeps patients in programs? J Am Heart Assoc. 2013;2:e000418. doi:10.1161/JAHA.113.000418
   PubMed Web of Science ®Google Scholar
• Chrystyn H, Small M, Milligan G, Higgins V, Gil E, Estruch J. Impact of patients’ satisfaction with their inhalers on treatment compliance and health status in COPD. Respir Med. 2014;108:358–365. doi:10.1016/j.rmed.2013.09.021
   PubMed Web of Science ®Google Scholar
• Wong W, Chow Y, Chen P, Wong S, Fielding R. A longitudinal analysis on pain treatment satisfaction among Chinese patients with chronic pain: predictors and association with medical adherence, disability, and quality of life. Qual Life Res. 2015;24:2087–2097. doi:10.1007/s11136-015-0955-1
   Web of Science ®Google Scholar
• Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig. 2010;30:89–100. doi:10.2165/11533330-000000000-00000
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292‐302. doi:10.1002/ana.22366
   Web of Science ®Google Scholar
• Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7:36. doi:10.1186/1477-7525-7-36
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale EDSS. Neurology. 1983;33(11):1444–1452. doi:10.1212/WNL.33.11.1444
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation Expert Working Group. ICH harmonized tripartite guideline guideline for good clinical practice E6(R1); 2016. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf. accessed November 11, 2015.
   Google Scholar
• World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects; 2016. Available from: http://www.wma.net/en/30publications/10policies/b3/17c.pdf. accessed November 11, 2015.
   Google Scholar
• Haase R, Kullmann JS, Ziemssen T. Therapy satisfaction and adherence in patients with relapsing–remitting multiple sclerosis: the THEPA-MS survey. Ther Adv Neurol Disord. 2016;9:250–263. doi:10.1177/1756285616634247
   PubMed Web of Science ®Google Scholar
• Hanson K, Agashivala N, Stringer S, Balantac Z, Brandes D. A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimod. Patient Prefer Adherence. 2013;309. doi:10.2147/PPA.S41992
   Web of Science ®Google Scholar
• Glanz BI, Musallam A, Rintell DJ, Chitnis T, Weiner HL, Healy BC. Treatment Satisfaction in Multiple Sclerosis. Int J MS Care. 2014;16:68–75. doi:10.7224/1537-2073.2013-021
   Google Scholar
• Coyle PK, Khatri B, Edwards KR, et al. Patient-reported outcomes in relapsing forms of MS: real-world, global treatment experience with teriflunomide from the Teri-PRO study. Mult Scler Relat Disord. 2017;17:107–115. doi:10.1016/j.msard.2017.07.006
   PubMed Web of Science ®Google Scholar
• Eagle T, Stuart F, Chua AS, et al. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis. Mult Scler Relat Disord. 2017;18:196–201. doi:10.1016/j.msard.2017.10.002
   Web of Science ®Google Scholar
• Fernández O, Duran E, Ayuso T, Hernández L, Bonaventura I, Forner M, on behalf of the STICK Study Investigators Group. Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study). PLoS One. 2017;12:e0185766. doi:10.1371/journal.pone.0185766.
   Web of Science ®Google Scholar
• Mékiès C, Heinzlef O, Jenny B, Ramelli A-L, Clavelou P. Treatment satisfaction and quality of life in patients treated with fingolimod. Patient Prefer Adherence. 2018;12:899–907. doi:10.2147/PPA.S144021
   Web of Science ®Google Scholar
• Brola W, Sobolewski P, Fudala M, et al. Self-reported quality of life in multiple sclerosis patients: preliminary results based on the Polish MS Registry. Patient Prefer Adherence. 2016;10:1647–1656. doi:10.2147/PPA.S109520
   PubMed Web of Science ®Google Scholar
• Gross HJ, Watson C. Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. Neuropsychiatr Dis Treat. 2017;13:1349–1357. doi:10.2147/NDT.S132079
   PubMed Web of Science ®Google Scholar
• Vermersch P, Hobart J, Dive-Pouletty C, Bozzi S, Hass S, Coyle PK. Measuring treatment satisfaction in MS: is the treatment satisfaction questionnaire for medication fit for purpose? Mult Scler J. 2017;23:604–613. doi:10.1177/1352458516657441
   PubMed Web of Science ®Google Scholar
• Calkwood J, Cree B, Crayton H, et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurol. 2014;14. doi:10.1186/s12883-014-0220-1.
   Web of Science ®Google Scholar